Kamada Ltd. logo
Kamada Ltd. KMDA
$ 6.95 -1.56%

Annual report 2024
added 10-25-2025

report update icon

Kamada Ltd. Net Debt 2011-2025 | KMDA

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Kamada Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- -70.2 M -38.4 M -17.4 M -11.3 M -8.19 M -4.86 M -7.1 M -42.9 M 7.25 M -1.94 M
202420242023202320222022202120212020202020192019201820182017201720162016201520152014201420132013201220122011201120 M20 M00-20 M-20 M-40 M-40 M-60 M-60 M-80 M-80 M
Download SVG
Download PNG
Download CSV

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
7.25 M -70.2 M -19.5 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
Graybug Vision Graybug Vision
GRAY
-33.4 M $ 0.44 -11.23 % $ 9.65 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M $ 11.3 -10.17 % $ 12.2 K -
Galera Therapeutics Galera Therapeutics
GRTX
-19.8 M $ 0.14 -32.59 % $ 7.61 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
1.09 M $ 4.37 -1.58 % $ 28.1 M chinaChina
Axon Enterprise Axon Enterprise
AXON
-404 M $ 755.0 0.8 % $ 57.2 B usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
-22.3 M $ 0.43 -16.75 % $ 25.8 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
85.5 M $ 0.27 -29.58 % $ 126 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-2.44 B $ 184.71 0.49 % $ 251 B cayman-islandsCayman-islands
ContraFect Corporation ContraFect Corporation
CFRX
-6.03 M $ 1.47 -5.16 % $ 5.39 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
-39 M $ 4.93 1.02 % $ 90.8 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M $ 0.29 -18.52 % $ 27.3 M britainBritain
Advaxis Advaxis
ADXS
3.42 M $ 0.31 -9.65 % $ 45.9 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
-9.08 M $ 3.93 -5.76 % $ 99.8 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
-46.4 M $ 6.2 - $ 154 M usaUSA
Zymeworks Zymeworks
ZYME
-200 M $ 6.42 - $ 404 M canadaCanada
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M $ 5.72 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-12.1 M $ 10.5 - $ 231 M usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
-71.4 M $ 9.5 - $ 1.7 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
-33.1 M $ 2.58 -4.8 % $ 255 M usaUSA
Mesoblast Limited Mesoblast Limited
MESO
-50.2 M $ 16.73 0.12 % $ 10.9 B australiaAustralia
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
-6.36 M $ 0.56 7.23 % $ 2.72 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K $ 0.5 - $ 7.46 M israelIsrael
Kiromic BioPharma Kiromic BioPharma
KRBP
-224 K $ 3.15 6.61 % $ 3.08 M usaUSA
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
-654 M $ 179.68 - $ 10.9 B usaUSA
Moderna Moderna
MRNA
-1.87 B $ 25.35 -4.91 % $ 9.73 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
-239 M $ 44.15 -0.23 % $ 916 M usaUSA
Merus N.V. Merus N.V.
MRUS
-283 M $ 94.9 0.32 % $ 6.09 B niderlandNiderland
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
-14.8 M $ 0.32 - $ 23.9 M usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
-247 M $ 18.44 - $ 1.94 B canadaCanada
Kaleido Biosciences Kaleido Biosciences
KLDO
-25.2 M $ 0.29 -3.69 % $ 12.4 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
-55.1 M $ 2.19 - $ 105 M usaUSA
Humanigen Humanigen
HGEN
-45 M $ 0.04 -81.12 % $ 4.28 M usaUSA
Aptinyx Aptinyx
APTX
-33.8 M $ 0.06 -39.0 % $ 4.57 M usaUSA
Tyme Technologies Tyme Technologies
TYME
-107 M $ 0.31 8.07 % $ 54 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
-57.9 M $ 2.64 -0.75 % $ 18.7 M danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M $ 0.39 - $ 26.5 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
-38.1 M $ 0.47 - $ 12.5 M belgiumBelgium
Nektar Therapeutics Nektar Therapeutics
NKTR
82.5 M $ 60.92 -2.64 % $ 11.6 B usaUSA
Brickell Biotech Brickell Biotech
BBI
-29.7 M $ 2.11 -5.38 % $ 6.06 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
-30.7 M $ 0.05 -15.0 % $ 3.04 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
-39.4 M $ 0.06 -55.98 % $ 2.15 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
-127 M $ 8.37 - $ 401 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-1.04 M $ 3.17 1.93 % $ 17.4 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
-56.5 M $ 0.37 -10.95 % $ 876 K usaUSA
Ocular Therapeutix Ocular Therapeutix
OCUL
-385 M $ 11.53 -0.17 % $ 1.82 B usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
-44.7 M $ 20.01 - $ 958 M usaUSA
Oragenics Oragenics
OGEN
-11.1 M $ 1.29 -2.27 % $ 2.9 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
-25.4 M $ 49.55 -6.81 % $ 3.04 B usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
-13.7 M $ 1.22 0.83 % $ 115 M canadaCanada